August 2016, Volume 2, Issue 8

August 2016

Volume 2, Issue 8

This issue examines the use of companion diagnostics, features patient education on acute myeloid leukemia, and provides coverage from the 2016 ASH Meeting on Lymphoma Biology.

Table of Contents

August 2016

Prescription for a patient with type 1 von Willebrand disease who is about to...

Monday, August 1st, 2016
Here's how readers responded to a You Make the Call question about a patient with type 1 von Willebrand disease who is about to undergo...

Conflict of Conscience

Monday, August 1st, 2016
On the first Wednesday of every month, the Innovation Management and Conflict of Interest Committee at Cleveland Clinic meets to discuss some of the...

August 2016

Remembering Philip W. Majerus, MD, ASH and APEX awards, and more

Monday, August 1st, 2016
Philip W. Majerus, MD (1936-2016) After a long illness, Philip W. Majerus, MD, died at home on June 8, 2016. He was 79. For hematologists,...

ASH Partners With LLS, Call for Blood Advances Papers, and more

Monday, August 1st, 2016
ASH and The Leukemia & Lymphoma Society Announce Collaboration on Acute Myeloid Leukemia The American Society of Hematology (ASH) and The Leukemia & Lymphoma Society...

August 2016

In Good Company: Have Companion Diagnostics Proven Their Mettle?

Monday, August 1st, 2016
Advances in the evolving field of precision medicine have led to the development of therapies that target specific biologic, including molecular, abnormalities. Companion diagnostics...

August 2016

What to prescribe for a patient with type 1 von Willebrand disease who is...

Monday, August 1st, 2016
This month, Barbara A. Konkle, MD, answers a question about what to prescribe for a patient with type 1 von Willebrand disease who is...

What Is Acute Myeloid Leukemia?

Monday, August 1st, 2016
Acute myeloid leukemia (AML) is the most common acute leukemia in the United States, comprising 33 percent of all leukemias. The cancer progresses rapidly...

August 2016

Hydrocortisone Helps Reduce Serious Neuropsychologic Adverse Events for Pediatric Acute Lymphocytic Leukemia Patients Receiving...

Monday, August 1st, 2016
While dexamethasone is a common component of the treatment of pediatric acute lymphocytic leukemia (ALL), the drug can cause serious neuropsychologic and metabolic adverse...

National Institutes of Health Funds Study of Zika Virus Exposure in Olympic Athletes

Monday, August 1st, 2016
The National Institutes of Health’s (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is funding a research initiative to...

First Trial to Use CRISPR in Humans Approved by Federal Biosafety and Ethics Panel

Monday, August 1st, 2016
A federal biosafety and ethics panel approved the first-in-human study of the genome-editing technology CRISPR-Cas9 to create genetically altered immune cells to attack three...

Researchers Identify 11 Different Subtypes of Acute Myeloid Leukemia

Monday, August 1st, 2016
In an analysis of more than 100 genes known to cause acute myeloid leukemia (AML), researchers from the Memorial Sloan Kettering Cancer Center in...

European Commission Approves First Gene Therapy for “Bubble Boy Disease”

Monday, August 1st, 2016
The European Commission approved the first gene therapy for children with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), also known as “bubble...

Ibrutinib Granted Breakthrough Therapy Designation for Chronic Graft-Versus-Host Disease

Monday, August 1st, 2016
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the tyrosine kinase inhibitor ibrutinib for the treatment of patients with...

NIH Finalizes Single Institutional Review Board Policy for Multiple-Site Studies

Monday, August 1st, 2016
On June 20, 2016, the National Institutes of Health (NIH) finalized a policy that permits a single Institutional Review Board (IRB) to review human...

Vice President Biden Unveils New Open-Access Database to Improve Cancer Research

Monday, August 1st, 2016
As part of the Cancer Moonshot Initiative, Vice President Joe Biden recently announced the Genomic Data Commons (GDC), a next-generation, open-access cancer database that provides data...
WIB_icon

Examining Idelalisib-Associated Hepatotoxicity in Patients with Chronic Lymphocytic Leukemia

Monday, August 1st, 2016
The PI3K inhibitor idelalisib (in combination with rituximab) is effective in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL), prompting investigators to evaluate...

Adding Ixazomib to Lenalidomide and Dexamethasone Results in Longer Progression-Free Survival in Patients with...

Monday, August 1st, 2016
Treatment with ixazomib plus lenalidomide and dexamethasone increased progression-free survival (PFS) by approximately six months – and with limited additional toxic effects – compared...

SIRIUS: Examining the Safety and Efficacy of Daratumumab in Heavily Pretreated Multiple Myeloma Patients

Monday, August 1st, 2016
The anti-CD38 monoclonal antibody daratumumab led to an overall response rate (ORR) of 29 percent in patients with multiple myeloma (MM) who were refractory...
WIB_icon

Brentuximab Vedotin Leads to Long-Term Remissions in Patients with Relapsed/Refractory Hodgkin Lymphoma

Monday, August 1st, 2016
In 2011, the U.S. Food and Drug Administration approved the CD30 antibody-drug conjugate brentuximab vedotin for the treatment of patients with Hodgkin lymphoma (HL)...

Disseminated Intravascular Coagulation: A Predictor for Arterial and Venous Thrombosis in Patients with Acute...

Monday, August 1st, 2016
About 10 percent of adult patients with acute myeloid leukemia (AML) treated with intensive chemotherapy developed venous or arterial thrombosis, according to results from...

August 2016

When Is it Safe for Patients with Chronic Myeloid Leukemia to Stop Tyrosine...

Monday, August 1st, 2016
With the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, dasinitib, or nilotinib, patients with chronic myeloid leukemia (CML) experience longer survival and...

Caplacizumab Plus Standard Care Reduces Thromboembolic Events, Mortality in Patients with Thrombotic Thrombocytopenia Purpura

Monday, August 1st, 2016
The standard of care for thrombotic thrombocytopenia purpura (TTP) is plasma exchange and immunosuppression, though many patients remain at risk for thrombotic complications until...

R-EPOCH May Be Viable Option for Patients with High-Risk DLBCL

Monday, August 1st, 2016
Results from a single-center study show that the drug combination R-EPOCH leads to a high overall response rate (ORR) in patients with high-risk diffuse...

Ibrutinib Shows Survival Benefit in Previously Treated CLL/SLL Patients with High-Risk Disease

Monday, August 1st, 2016
Longer-term data from the phase III RESONATE trial – a head-to-head comparison of ibrutinib and ofatumumab – continue to demonstrate ibrutinib’s efficacy in patients...

Inotuzumab Ozogamicin Results in Longer Overall Survival Versus Standard Care for ALL

Monday, August 1st, 2016
In an update from the ongoing phase III INO-VATE trial, treatment with inotuzumab ozogamicin prolonged overall survival (OS) and progression-free survival (PFS) in patients...

Masitinib Improves Symptom Burden, Responses in Patients with Severe Systemic Mastocytosis

Monday, August 1st, 2016
Masitinib, a selective oral tyrosine kinase inhibitor (TKI) targeting wild-type KIT, LYN, and FYN, reduced the severity of a diverse range of symptoms in...

POLLUX Trial: Triplet Daratumumab Combination Reduces Risk of Disease Progression in Relapsed/Refractory Myeloma

Monday, August 1st, 2016
Combining the anti-CD38 antibody daratumumab with lenalidomide and dexamethasone led to a lower risk of disease progression and death, compared with lenalidomide and dexamethasone...

Tazemetostat for Patients with Pretreated Non-Hodgkin Lymphoma

Monday, August 1st, 2016
Preliminary data from an ongoing, global, phase II trial of tazemetostat, a first-in-class EZH2 inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma (NHL)...

SHARE